Досрочное прекращение приема двухкомпонентной антиагрегантной терапии после перенесенного острого коронарного синдрома: клинические последствия и современные подходы к решению проблемы

1. Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention (ASSENT-4 PCI) investigators. Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial. Lancet 2006; 367: 569–78.
2. Armstrong PW, Granger CB, Adams PX et al. Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: a randomized controlled trial. JAMA 2007; 297: 43–51.
3. Montalescot G, Wiviott SD, Braunwald E et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 2009; 373: 723–31.
4. Tebbe U, Messer C, Stammwitz E et al. Reduction of in-hospital mortality and improved secondary prevention after acute myocardial infarction. First results from the registry of secondary prevention after acute myocardial infarction (SAMI). Dtsch Med Wochenschr 2007; 132: 1559–66.
5. Buch P, Rasmussen S, Gislason GH et al. Temporal decline in the prognostic impact of a recurrent acute myocardial infarction 1985 to 2002. Heart 2007; 93: 210–5.
6. Fox KA, Dabbous OH, Goldberg RJ et al. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). BMJ 2006; 333: 1091–4.
7. Fuster V, Badimon L, Badimon JJ et al. Mechanisms of disease - the pathogenesis of coronary-artery disease and the acute coronary syndromes. N Engl J Med 1992; 326: 310–8.
8. Lange RA, Hillis LD. Antiplatelet therapy for ischemic heart disease. N Engl J Med 2004; 350: 277–80.
9. Dorsam RT, Kunapuli SP. Central role of the P2Y12 receptor in platelet activation. J Clin Invest 2004; 113: 340–5.
10. Gachet C. Regulation of platelet functions by P2 receptors. Annu Rev Pharmacol Toxicol 2006; 46: 277–300.
11. Patrono C, Baigent C, Hirsh J, Roth G on behalf of American College of Chest Physicians. Antiplatelet drugs: American College of  Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest 2008; 133 (Suppl. 6): 199S–233S.
12. Kushner FG, Hand M, Smith SC Jr et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2009; 54: 2205–41.
13. Van de Werf F, Bax J, Betriu A et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2008; 29: 2909–45. 
14. Hamm CW, Bassand JP, Agewall S et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011 [Epub ahead of print].
15. Anderson JL, Adams CD, Antman EM et al. 2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011; 123: e426–579.
16. Ho PM, Tsai TT, Maddox TM et al. Delays in filling clopidogrel prescription after hospital discharge and adverse outcomes after drug-eluting stent implantation: implications for transitions of care. Circ Cardiovasc Qual Outcomes 2010; 3: 261–6. 
17. Daskalopoulou SS, Delaney JAC, Filion KB et al. Discontinuation of statin therapy following an acute myocardial infarction: a population-based study. Eur Heart J 2008; 29: 2083–91.
18. Boggon R, van Staa TP, Timmis A et al. Clopidogrel discontinuation after acute coronary syndromes: frequency, predictors and associations with death and myocardial infarction – a hospital registry-primary care linked cohort (MINAP-GPRD). 
Eur Heart J 2011 [Epub ahead of print].
19. Spertus JA, Kettelkamp R, Vance C et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation 2006; 113: 2803–9.
20. Eikelboom JW, Hirsh J. Bleeding and management of bleeding. Eur Heart J 2006; 8 Suppl.: G38–G45.
21. Valerin MA, Brennan MT, Noll JL et al. Relationship between aspirin use and postoperative bleeding from dental extractions in a healthy population. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006; 102: 326.
22. Lockhart PB, Gibson J, Pond SH, Leitch J. Dental management considerations for the patient with an acquired coagulopathy: part II: coagulopathies from drugs. Br Dent J 2003; 195: 495–501.
23. McDonald SB, Renna M, Spitznagel EL et al. Preoperative use of enoxaparin increases the risk of postoperative bleeding and re-exploration in cardiac surgery patients. J Cardiothorac Vasc Anesth 2005; 19: 4–10.
24. Mixed thoughts on how generic clopidogrel might impact patients, providers. HeartWire; August 11, 2006. Available at: http://www.theheart.org/article/729929.do. Accessed November 2006.
25. Haas JS, Phillips KA, Gerstenberger EP, Seger AC. Potential Savings from Substituting Generic Drugs for Brand-Name Drugs: Medical Expenditure Panel Survey, 1997–2000. Ann Intern Med 2005; 142: 891–7.
26. Prescription Drug Trends: a Chartbook Update. Menlo Park, CA: Henry J. Kaiser Family Foundation; 2001.
27. Strom BL. Generic drug substitution revisited. N Engl J Med 1987; 316 (23): 1456–62.
28. Nightingale SL. From the Food and Drug Administration. JAMA1998; 279: 645.
29. 21 CFR §320.1 2000.
30. Shrank W, Cox E, Fischer MA et al. Patient perceptions of generic medications. Health Aff 2009; 28: 546–56.
31. Banahan BF, Bonnarens JK, Bentley JP. Generic substitution of NTI drugs. Formulary 1998; 33: 1082–96.
32. Gaither C, Kirking D, Ascione F, Welage L. Consumers’ views on generic medications. J Am Pharm Assoc 2001; 41: 729–36.
33. Saul S, Berenson A. Maker of Lipitor digs in to fight generic rival. New York Times 2007: A1.
34. Kesselheim AS, Misono AS, Lee JL et al. Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis. JAMA 2008; 300: 2514–26.
35. Ashraf T, Ahmed M, Talpur MS et al. Competency profile of locally manufactured clopidogrel Lowplat and foreign manufactured clopidogrel Plavix in patients of suspected ischemic heart disease. J Pak Med Assoc 2005; 55: 443–8.
36. Rao TR, Usha PR, Naidu MU et al. Bioequivalence and tolerability study of two brands of clopidogrel tablets, using inhibition of platelet aggregation and pharmacodynamic measures. Curr Ther Res Clin Exp 2003; 64: 685–96.
37. The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J 2007: 28: 1598–660.
38. The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation. Eur Heart J 2008; 29: 2909–45.
39. Гиляревский С.Р., Ларин А.Г., Лопотовский П.Ю. и др. Сравнение антиагрегантного действия оригинального препарата клопидогрела Плавикса и его генерического аналога Лопирела у больных с острым коронарным синдромом, которым выполнялись первичные чрескожные вмешательства на коронарных артериях. Русский медицинский журнал. 2011;19 (4): 263–7.
40. Паскалева И., Динева Д., Георгиев Б., Байчева В. Ефект на клопидогрел (ACTAVIS) върху АДФ-индуцираната тромбоцитна агрегация, проследена в 30-дневен период. Наука кардиология. 2008: 3: 140–4.

С.Р.Гиляревский, А.Г.Ларин, П.Ю.Лопотовский, И.М.Кузьмина, О.В.Батурина, Х.Р.Келехсаев

НИИ скорой помощи им. Н.В.Склифосовского, Москва